Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer (Early Breast Cancer), Postoperative Shoulder Dysfunction
Prehabilitation in Breast Cancer Surgery
This prospective, randomized, assessor-blinded, parallel-group clinical trial evaluates the effectiveness of a home-based upper extremity-focused prehabilitation program in women undergoing breast cancer surgery.
- Conditions
- Breast Cancer (Early Breast Cancer), Postoperative Shoulder Dysfunction, Lymphedema Arm, Cancer Rehabilitation
- Trial name
- NCT07425379
- Testing
- Home-Based Prehabilitation Exercise Program, Usual Care
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
HER2-positive Early Breast Cancer
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
This study will evaluate the pharmacokinetics, efficacy, and safety of the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) as compared with those of the pertuzumab intravenous (IV)…
- Trial name
- NCT04024462
- Testing
- Pertuzumab IV, Trastuzumab IV, Pertuzumab and Trastuzumab FDC SC
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer, Early-stage Breast Cancer
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer.
- Trial name
- DEFINITIVE (NCT06446882)
- Testing
- Personalized treatment according to molecular diagnosis with HER2DX, Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
- Where
- 29 sites in Austria, France and 3 more
- Volunteers
- 304 people
- Sponsor
- Fundacio Clinic Barcelona
Early Triple Negative Breast Cancer
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC).
- Trial name
- NCT06829199
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 2 sites in United States, Taiwan
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Early Breast Cancer
Correlation Between Tumor-infiltrating Lymphocytes and Response to Systemic Therapy in Breast Cancer
This study aims to investigate the correlation between immune-related factors in the tumor stroma and pathological complete response (pCR) in patients with early breast cancer treated with neoadjuvant chemotherapy.
- Trial name
- NCT07404462
- Testing
- Standard-of-Care Neoadjuvant Chemotherapy
- Where
- Slovenia
- Volunteers
- 171 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Early Gastric Cancer, Advanced Gastric Cancer
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a…
- Conditions
- Early Gastric Cancer, Advanced Gastric Cancer, Early Lung Cancer, Advanced Lung Cancer
- Trial name
- NCT07405931
- Testing
- Standardized Telenursing, Smart Cancer Care Plus
- Where
- 5 sites in South Korea
- Volunteers
- 414 people
- Sponsor
- Ulsan University Hospital
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy…
- Trial name
- HER2BREASTDX (NCT06723990)
- Testing
- Neoadjuvant standard treatment for HER2+, Adjuvant standard treatment for HER2+
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Early Breast Cancer, Metastatic Breast Cancer
Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
This trial is a translational, open-label, monocentric and prospective cohort study of participants with breast cancer aiming to create a combined ESPRESSO (= organelle properties) phenotype and spatial proteomics data collection…
- Trial name
- ESPRESSOBREAST (NCT07233928)
- Testing
- Tumor biopsy
- Where
- France
- Volunteers
- 1,050 people
- Sponsor
- Institut Claudius Regaud
Early Breast Cancer
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer.
- Trial name
- POSITIVE (NCT02308085)
- Testing
- Endocrine therapy interruption
- Where
- 211 sites in United States, Australia and 20 more
- Volunteers
- 518 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Early-Onset
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Primary Objective: 1) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery…
- Trial name
- NCT05333874
- Testing
- Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Early Stage Breast Cancer
Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant
Permanent Breast Seed Implant (PBSI) has been demonstrated to be a well accepted and well tolerated form of partial breast radiotherapy.
- Trial name
- PBSI (NCT02297672)
- Testing
- Stranded palladium seed interstitial implant, 3 dimensional breast ultrasound, Computerized tomography (CT)
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- British Columbia Cancer Agency
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
Praegnant Breast Cancer: Early/Advanced/Metastatic
Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis.
- Trial name
- PRAEGNANT (NCT02338167)
- Testing
- Blood sampling
- Where
- 61 sites in Germany
- Volunteers
- 13,500 people
- Sponsor
- University Hospital Tuebingen
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer
This is a multicenter, observational validation study designed to evaluate the prognostic performance of the PORTENT algorithm in patients with early-stage breast cancer.
- Trial name
- PORTENT (NCT07372261)
- Testing
- Validation of Prognostic tool
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer
This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer.
- Trial name
- NCT07373782
- Testing
- Continuous Positive Airway Pressure (CPAP)
- Where
- Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT06324240
- Testing
- Ipilimumab, Pembrolizumab, Vaccine Therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
HER2-positive Early Breast Cancer
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
This prospective, response-guided phase II study investigates individualized neoadjuvant treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
- Trial name
- TAYLOR (NCT07340398)
- Testing
- Nab paclitaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Prehabilitation
Multimodal Prehabilitation Program That Combines Physical Exercise, Psychological Intervention and Nutritional Support to Improve the Response to Neoadjuvant Chemoterhapy in Early Breast Cancer Patients
The aim of this clinical trial is to evaluate whether following a multimodal prehabilitation program including physical exercise, nutritional support and psychological intervention during neoadjuvant chemotherapy in breast cancer…
- Trial name
- DIANA (NCT07107594)
- Testing
- Multimodal prehabilitation
- Where
- Spain
- Volunteers
- 214 people
- Sponsor
- Hospital Clinic of Barcelona